nodes	percent_of_prediction	percent_of_DWPC	metapath
Ranolazine—Altered state of consciousness—Vincristine—muscle cancer	0.0299	0.0305	CcSEcCtD
Ranolazine—Pulmonary fibrosis—Etoposide—muscle cancer	0.0254	0.0259	CcSEcCtD
Ranolazine—Throat tightness—Etoposide—muscle cancer	0.0228	0.0232	CcSEcCtD
Ranolazine—Nephropathy toxic—Etoposide—muscle cancer	0.0195	0.0198	CcSEcCtD
Ranolazine—Carvedilol—VEGFA—muscle cancer	0.0187	1	CrCbGaD
Ranolazine—Pulmonary fibrosis—Methotrexate—muscle cancer	0.0152	0.0155	CcSEcCtD
Ranolazine—Gait disturbance—Vincristine—muscle cancer	0.0141	0.0144	CcSEcCtD
Ranolazine—Lethargy—Dactinomycin—muscle cancer	0.0114	0.0117	CcSEcCtD
Ranolazine—Pain in extremity—Vincristine—muscle cancer	0.01	0.0102	CcSEcCtD
Ranolazine—Urinary retention—Vincristine—muscle cancer	0.00953	0.00971	CcSEcCtD
Ranolazine—Serum creatinine increased—Doxorubicin—muscle cancer	0.00943	0.00961	CcSEcCtD
Ranolazine—Thrombocytosis—Doxorubicin—muscle cancer	0.00933	0.0095	CcSEcCtD
Ranolazine—Dehydration—Vincristine—muscle cancer	0.00932	0.0095	CcSEcCtD
Ranolazine—Pancytopenia—Dactinomycin—muscle cancer	0.00921	0.00938	CcSEcCtD
Ranolazine—Parosmia—Doxorubicin—muscle cancer	0.00894	0.00911	CcSEcCtD
Ranolazine—Pancytopenia—Vincristine—muscle cancer	0.00822	0.00838	CcSEcCtD
Ranolazine—Dysuria—Vincristine—muscle cancer	0.0081	0.00825	CcSEcCtD
Ranolazine—Erectile dysfunction—Vincristine—muscle cancer	0.00798	0.00813	CcSEcCtD
Ranolazine—Dermatitis atopic—Doxorubicin—muscle cancer	0.00784	0.00798	CcSEcCtD
Ranolazine—Weight decreased—Vincristine—muscle cancer	0.00784	0.00798	CcSEcCtD
Ranolazine—Cramp muscle—Etoposide—muscle cancer	0.00731	0.00745	CcSEcCtD
Ranolazine—Hallucination—Vincristine—muscle cancer	0.0069	0.00703	CcSEcCtD
Ranolazine—Hypoaesthesia—Vincristine—muscle cancer	0.0069	0.00703	CcSEcCtD
Ranolazine—Urinary tract disorder—Vincristine—muscle cancer	0.00685	0.00698	CcSEcCtD
Ranolazine—Connective tissue disorder—Vincristine—muscle cancer	0.00681	0.00694	CcSEcCtD
Ranolazine—Urethral disorder—Vincristine—muscle cancer	0.0068	0.00692	CcSEcCtD
Ranolazine—Pancytopenia—Etoposide—muscle cancer	0.00666	0.00679	CcSEcCtD
Ranolazine—Depressed level of consciousness—Methotrexate—muscle cancer	0.00647	0.00659	CcSEcCtD
Ranolazine—Cardiac disorder—Vincristine—muscle cancer	0.00643	0.00656	CcSEcCtD
Ranolazine—Angiopathy—Vincristine—muscle cancer	0.00629	0.00641	CcSEcCtD
Ranolazine—Mediastinal disorder—Vincristine—muscle cancer	0.00625	0.00637	CcSEcCtD
Ranolazine—Renal failure—Etoposide—muscle cancer	0.00615	0.00627	CcSEcCtD
Ranolazine—Creatinine increased—Doxorubicin—muscle cancer	0.00609	0.00621	CcSEcCtD
Ranolazine—Mental disorder—Vincristine—muscle cancer	0.00607	0.00619	CcSEcCtD
Ranolazine—Leukopenia—Dactinomycin—muscle cancer	0.00605	0.00616	CcSEcCtD
Ranolazine—Gait disturbance—Doxorubicin—muscle cancer	0.00594	0.00606	CcSEcCtD
Ranolazine—Coordination abnormal—Doxorubicin—muscle cancer	0.00591	0.00602	CcSEcCtD
Ranolazine—Hypoaesthesia—Etoposide—muscle cancer	0.00559	0.00569	CcSEcCtD
Ranolazine—Urinary tract disorder—Etoposide—muscle cancer	0.00555	0.00565	CcSEcCtD
Ranolazine—Urethral disorder—Etoposide—muscle cancer	0.0055	0.00561	CcSEcCtD
Ranolazine—Blood urea increased—Doxorubicin—muscle cancer	0.00548	0.00558	CcSEcCtD
Ranolazine—Vertigo—Vincristine—muscle cancer	0.00542	0.00552	CcSEcCtD
Ranolazine—Leukopenia—Vincristine—muscle cancer	0.0054	0.0055	CcSEcCtD
Ranolazine—Thrombocytopenia—Dactinomycin—muscle cancer	0.0054	0.0055	CcSEcCtD
Ranolazine—Renal failure acute—Methotrexate—muscle cancer	0.00527	0.00537	CcSEcCtD
Ranolazine—Anorexia—Dactinomycin—muscle cancer	0.00525	0.00535	CcSEcCtD
Ranolazine—Eye disorder—Etoposide—muscle cancer	0.00525	0.00535	CcSEcCtD
Ranolazine—Cardiac disorder—Etoposide—muscle cancer	0.00521	0.00531	CcSEcCtD
Ranolazine—Visual disturbance—Methotrexate—muscle cancer	0.00513	0.00523	CcSEcCtD
Ranolazine—Angiopathy—Etoposide—muscle cancer	0.00509	0.00519	CcSEcCtD
Ranolazine—Mediastinal disorder—Etoposide—muscle cancer	0.00506	0.00516	CcSEcCtD
Ranolazine—Lethargy—Methotrexate—muscle cancer	0.00496	0.00506	CcSEcCtD
Ranolazine—Nervous system disorder—Vincristine—muscle cancer	0.00483	0.00492	CcSEcCtD
Ranolazine—Thrombocytopenia—Vincristine—muscle cancer	0.00482	0.00491	CcSEcCtD
Ranolazine—Decreased appetite—Dactinomycin—muscle cancer	0.00479	0.00488	CcSEcCtD
Ranolazine—Hyperhidrosis—Vincristine—muscle cancer	0.00476	0.00485	CcSEcCtD
Ranolazine—Fatigue—Dactinomycin—muscle cancer	0.00475	0.00484	CcSEcCtD
Ranolazine—Muscle spasms—Etoposide—muscle cancer	0.0047	0.00479	CcSEcCtD
Ranolazine—Anorexia—Vincristine—muscle cancer	0.00469	0.00478	CcSEcCtD
Ranolazine—Hypotension—Vincristine—muscle cancer	0.0046	0.00469	CcSEcCtD
Ranolazine—Renal failure acute—Doxorubicin—muscle cancer	0.00456	0.00465	CcSEcCtD
Ranolazine—Feeling abnormal—Dactinomycin—muscle cancer	0.00454	0.00463	CcSEcCtD
Ranolazine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00451	0.00459	CcSEcCtD
Ranolazine—Hot flush—Doxorubicin—muscle cancer	0.0045	0.00459	CcSEcCtD
Ranolazine—Menopausal symptoms—Doxorubicin—muscle cancer	0.00446	0.00455	CcSEcCtD
Ranolazine—Insomnia—Vincristine—muscle cancer	0.00445	0.00454	CcSEcCtD
Ranolazine—Paraesthesia—Vincristine—muscle cancer	0.00442	0.00451	CcSEcCtD
Ranolazine—Breast disorder—Methotrexate—muscle cancer	0.00439	0.00448	CcSEcCtD
Ranolazine—Vertigo—Etoposide—muscle cancer	0.00439	0.00448	CcSEcCtD
Ranolazine—Leukopenia—Etoposide—muscle cancer	0.00438	0.00446	CcSEcCtD
Ranolazine—Abdominal pain—Dactinomycin—muscle cancer	0.00436	0.00444	CcSEcCtD
Ranolazine—Loss of consciousness—Etoposide—muscle cancer	0.0043	0.00438	CcSEcCtD
Ranolazine—Lethargy—Doxorubicin—muscle cancer	0.0043	0.00438	CcSEcCtD
Ranolazine—Decreased appetite—Vincristine—muscle cancer	0.00428	0.00436	CcSEcCtD
Ranolazine—Cough—Etoposide—muscle cancer	0.00427	0.00435	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Vincristine—muscle cancer	0.00425	0.00433	CcSEcCtD
Ranolazine—Fatigue—Vincristine—muscle cancer	0.00425	0.00433	CcSEcCtD
Ranolazine—Constipation—Vincristine—muscle cancer	0.00421	0.00429	CcSEcCtD
Ranolazine—Pain in extremity—Doxorubicin—muscle cancer	0.00421	0.00429	CcSEcCtD
Ranolazine—Diplopia—Doxorubicin—muscle cancer	0.00421	0.00429	CcSEcCtD
Ranolazine—Eosinophilia—Methotrexate—muscle cancer	0.00416	0.00424	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00413	0.00421	CcSEcCtD
Ranolazine—Pancreatitis—Methotrexate—muscle cancer	0.00412	0.0042	CcSEcCtD
Ranolazine—Abdominal discomfort—Methotrexate—muscle cancer	0.00403	0.00411	CcSEcCtD
Ranolazine—Gastrointestinal pain—Vincristine—muscle cancer	0.00403	0.0041	CcSEcCtD
Ranolazine—Confusional state—Etoposide—muscle cancer	0.00402	0.0041	CcSEcCtD
Ranolazine—Pancytopenia—Methotrexate—muscle cancer	0.00399	0.00407	CcSEcCtD
Ranolazine—Asthenia—Dactinomycin—muscle cancer	0.00395	0.00403	CcSEcCtD
Ranolazine—Blood creatinine increased—Doxorubicin—muscle cancer	0.00394	0.00402	CcSEcCtD
Ranolazine—Dysuria—Methotrexate—muscle cancer	0.00393	0.004	CcSEcCtD
Ranolazine—Dehydration—Doxorubicin—muscle cancer	0.00392	0.00399	CcSEcCtD
Ranolazine—Thrombocytopenia—Etoposide—muscle cancer	0.00391	0.00398	CcSEcCtD
Ranolazine—Abdominal pain—Vincristine—muscle cancer	0.00389	0.00397	CcSEcCtD
Ranolazine—Skin disorder—Etoposide—muscle cancer	0.00388	0.00395	CcSEcCtD
Ranolazine—Erectile dysfunction—Methotrexate—muscle cancer	0.00387	0.00394	CcSEcCtD
Ranolazine—Hyperhidrosis—Etoposide—muscle cancer	0.00386	0.00393	CcSEcCtD
Ranolazine—Orthostatic hypotension—Doxorubicin—muscle cancer	0.00385	0.00392	CcSEcCtD
Ranolazine—Breast disorder—Doxorubicin—muscle cancer	0.0038	0.00388	CcSEcCtD
Ranolazine—Anorexia—Etoposide—muscle cancer	0.0038	0.00388	CcSEcCtD
Ranolazine—Hypotension—Etoposide—muscle cancer	0.00373	0.0038	CcSEcCtD
Ranolazine—Renal failure—Methotrexate—muscle cancer	0.00368	0.00375	CcSEcCtD
Ranolazine—Eosinophilia—Doxorubicin—muscle cancer	0.0036	0.00367	CcSEcCtD
Ranolazine—Paraesthesia—Etoposide—muscle cancer	0.00358	0.00365	CcSEcCtD
Ranolazine—Haematuria—Methotrexate—muscle cancer	0.00357	0.00364	CcSEcCtD
Ranolazine—Pancreatitis—Doxorubicin—muscle cancer	0.00357	0.00364	CcSEcCtD
Ranolazine—Dyspnoea—Etoposide—muscle cancer	0.00356	0.00362	CcSEcCtD
Ranolazine—Somnolence—Etoposide—muscle cancer	0.00355	0.00361	CcSEcCtD
Ranolazine—Epistaxis—Methotrexate—muscle cancer	0.00353	0.0036	CcSEcCtD
Ranolazine—Asthenia—Vincristine—muscle cancer	0.00353	0.0036	CcSEcCtD
Ranolazine—Vomiting—Dactinomycin—muscle cancer	0.0035	0.00357	CcSEcCtD
Ranolazine—Rash—Dactinomycin—muscle cancer	0.00348	0.00354	CcSEcCtD
Ranolazine—Decreased appetite—Etoposide—muscle cancer	0.00347	0.00353	CcSEcCtD
Ranolazine—Pancytopenia—Doxorubicin—muscle cancer	0.00346	0.00352	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Etoposide—muscle cancer	0.00344	0.00351	CcSEcCtD
Ranolazine—Fatigue—Etoposide—muscle cancer	0.00344	0.0035	CcSEcCtD
Ranolazine—Constipation—Etoposide—muscle cancer	0.00341	0.00348	CcSEcCtD
Ranolazine—Dysuria—Doxorubicin—muscle cancer	0.0034	0.00347	CcSEcCtD
Ranolazine—Urinary tract disorder—Methotrexate—muscle cancer	0.00332	0.00338	CcSEcCtD
Ranolazine—Urethral disorder—Methotrexate—muscle cancer	0.0033	0.00336	CcSEcCtD
Ranolazine—Weight decreased—Doxorubicin—muscle cancer	0.00329	0.00335	CcSEcCtD
Ranolazine—Feeling abnormal—Etoposide—muscle cancer	0.00329	0.00335	CcSEcCtD
Ranolazine—Nausea—Dactinomycin—muscle cancer	0.00327	0.00334	CcSEcCtD
Ranolazine—Gastrointestinal pain—Etoposide—muscle cancer	0.00326	0.00332	CcSEcCtD
Ranolazine—Dizziness—Vincristine—muscle cancer	0.00326	0.00332	CcSEcCtD
Ranolazine—Visual impairment—Methotrexate—muscle cancer	0.00324	0.0033	CcSEcCtD
Ranolazine—Renal failure—Doxorubicin—muscle cancer	0.00319	0.00325	CcSEcCtD
Ranolazine—Urticaria—Etoposide—muscle cancer	0.00317	0.00323	CcSEcCtD
Ranolazine—Abdominal pain—Etoposide—muscle cancer	0.00315	0.00321	CcSEcCtD
Ranolazine—Eye disorder—Methotrexate—muscle cancer	0.00314	0.0032	CcSEcCtD
Ranolazine—Tinnitus—Methotrexate—muscle cancer	0.00314	0.0032	CcSEcCtD
Ranolazine—Vomiting—Vincristine—muscle cancer	0.00313	0.00319	CcSEcCtD
Ranolazine—Cardiac disorder—Methotrexate—muscle cancer	0.00312	0.00318	CcSEcCtD
Ranolazine—Rash—Vincristine—muscle cancer	0.00311	0.00316	CcSEcCtD
Ranolazine—Dermatitis—Vincristine—muscle cancer	0.0031	0.00316	CcSEcCtD
Ranolazine—Haematuria—Doxorubicin—muscle cancer	0.00309	0.00315	CcSEcCtD
Ranolazine—Headache—Vincristine—muscle cancer	0.00309	0.00314	CcSEcCtD
Ranolazine—Epistaxis—Doxorubicin—muscle cancer	0.00306	0.00312	CcSEcCtD
Ranolazine—Angiopathy—Methotrexate—muscle cancer	0.00305	0.00311	CcSEcCtD
Ranolazine—Mediastinal disorder—Methotrexate—muscle cancer	0.00303	0.00309	CcSEcCtD
Ranolazine—Bradycardia—Doxorubicin—muscle cancer	0.00296	0.00302	CcSEcCtD
Ranolazine—Mental disorder—Methotrexate—muscle cancer	0.00295	0.003	CcSEcCtD
Ranolazine—Malnutrition—Methotrexate—muscle cancer	0.00293	0.00298	CcSEcCtD
Ranolazine—Nausea—Vincristine—muscle cancer	0.00293	0.00298	CcSEcCtD
Ranolazine—Hypoaesthesia—Doxorubicin—muscle cancer	0.0029	0.00295	CcSEcCtD
Ranolazine—Urinary tract disorder—Doxorubicin—muscle cancer	0.00288	0.00293	CcSEcCtD
Ranolazine—Oedema peripheral—Doxorubicin—muscle cancer	0.00287	0.00292	CcSEcCtD
Ranolazine—Asthenia—Etoposide—muscle cancer	0.00286	0.00292	CcSEcCtD
Ranolazine—Connective tissue disorder—Doxorubicin—muscle cancer	0.00286	0.00292	CcSEcCtD
Ranolazine—Urethral disorder—Doxorubicin—muscle cancer	0.00285	0.00291	CcSEcCtD
Ranolazine—Pruritus—Etoposide—muscle cancer	0.00282	0.00288	CcSEcCtD
Ranolazine—Visual impairment—Doxorubicin—muscle cancer	0.00281	0.00286	CcSEcCtD
Ranolazine—Vision blurred—Methotrexate—muscle cancer	0.00276	0.00281	CcSEcCtD
Ranolazine—Eye disorder—Doxorubicin—muscle cancer	0.00272	0.00277	CcSEcCtD
Ranolazine—Tinnitus—Doxorubicin—muscle cancer	0.00272	0.00277	CcSEcCtD
Ranolazine—Cardiac disorder—Doxorubicin—muscle cancer	0.0027	0.00275	CcSEcCtD
Ranolazine—Angiopathy—Doxorubicin—muscle cancer	0.00264	0.00269	CcSEcCtD
Ranolazine—Dizziness—Etoposide—muscle cancer	0.00264	0.00269	CcSEcCtD
Ranolazine—Vertigo—Methotrexate—muscle cancer	0.00263	0.00268	CcSEcCtD
Ranolazine—Mediastinal disorder—Doxorubicin—muscle cancer	0.00262	0.00267	CcSEcCtD
Ranolazine—Leukopenia—Methotrexate—muscle cancer	0.00262	0.00267	CcSEcCtD
Ranolazine—Arrhythmia—Doxorubicin—muscle cancer	0.0026	0.00265	CcSEcCtD
Ranolazine—Cough—Methotrexate—muscle cancer	0.00256	0.0026	CcSEcCtD
Ranolazine—Mental disorder—Doxorubicin—muscle cancer	0.00255	0.0026	CcSEcCtD
Ranolazine—Vomiting—Etoposide—muscle cancer	0.00254	0.00258	CcSEcCtD
Ranolazine—Malnutrition—Doxorubicin—muscle cancer	0.00254	0.00258	CcSEcCtD
Ranolazine—Rash—Etoposide—muscle cancer	0.00252	0.00256	CcSEcCtD
Ranolazine—Dermatitis—Etoposide—muscle cancer	0.00251	0.00256	CcSEcCtD
Ranolazine—Headache—Etoposide—muscle cancer	0.0025	0.00255	CcSEcCtD
Ranolazine—Flatulence—Doxorubicin—muscle cancer	0.0025	0.00255	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.00248	0.00252	CcSEcCtD
Ranolazine—Muscle spasms—Doxorubicin—muscle cancer	0.00244	0.00248	CcSEcCtD
Ranolazine—Confusional state—Methotrexate—muscle cancer	0.00241	0.00246	CcSEcCtD
Ranolazine—Vision blurred—Doxorubicin—muscle cancer	0.00239	0.00243	CcSEcCtD
Ranolazine—Nausea—Etoposide—muscle cancer	0.00237	0.00241	CcSEcCtD
Ranolazine—Nervous system disorder—Methotrexate—muscle cancer	0.00234	0.00239	CcSEcCtD
Ranolazine—Thrombocytopenia—Methotrexate—muscle cancer	0.00234	0.00238	CcSEcCtD
Ranolazine—Skin disorder—Methotrexate—muscle cancer	0.00232	0.00237	CcSEcCtD
Ranolazine—Hyperhidrosis—Methotrexate—muscle cancer	0.00231	0.00235	CcSEcCtD
Ranolazine—Vertigo—Doxorubicin—muscle cancer	0.00228	0.00232	CcSEcCtD
Ranolazine—Anorexia—Methotrexate—muscle cancer	0.00228	0.00232	CcSEcCtD
Ranolazine—Syncope—Doxorubicin—muscle cancer	0.00227	0.00232	CcSEcCtD
Ranolazine—Leukopenia—Doxorubicin—muscle cancer	0.00227	0.00231	CcSEcCtD
Ranolazine—Palpitations—Doxorubicin—muscle cancer	0.00224	0.00228	CcSEcCtD
Ranolazine—Hypotension—Methotrexate—muscle cancer	0.00223	0.00228	CcSEcCtD
Ranolazine—Loss of consciousness—Doxorubicin—muscle cancer	0.00223	0.00227	CcSEcCtD
Ranolazine—Cough—Doxorubicin—muscle cancer	0.00221	0.00225	CcSEcCtD
Ranolazine—Insomnia—Methotrexate—muscle cancer	0.00216	0.0022	CcSEcCtD
Ranolazine—Anxiety—Doxorubicin—muscle cancer	0.00215	0.00219	CcSEcCtD
Ranolazine—Paraesthesia—Methotrexate—muscle cancer	0.00215	0.00219	CcSEcCtD
Ranolazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00214	0.00218	CcSEcCtD
Ranolazine—Dyspnoea—Methotrexate—muscle cancer	0.00213	0.00217	CcSEcCtD
Ranolazine—Somnolence—Methotrexate—muscle cancer	0.00212	0.00216	CcSEcCtD
Ranolazine—Dry mouth—Doxorubicin—muscle cancer	0.00211	0.00215	CcSEcCtD
Ranolazine—Dyspepsia—Methotrexate—muscle cancer	0.0021	0.00214	CcSEcCtD
Ranolazine—Confusional state—Doxorubicin—muscle cancer	0.00209	0.00213	CcSEcCtD
Ranolazine—Decreased appetite—Methotrexate—muscle cancer	0.00208	0.00212	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Methotrexate—muscle cancer	0.00206	0.0021	CcSEcCtD
Ranolazine—Fatigue—Methotrexate—muscle cancer	0.00206	0.0021	CcSEcCtD
Ranolazine—Shock—Doxorubicin—muscle cancer	0.00204	0.00207	CcSEcCtD
Ranolazine—Nervous system disorder—Doxorubicin—muscle cancer	0.00203	0.00207	CcSEcCtD
Ranolazine—Thrombocytopenia—Doxorubicin—muscle cancer	0.00203	0.00206	CcSEcCtD
Ranolazine—Skin disorder—Doxorubicin—muscle cancer	0.00201	0.00205	CcSEcCtD
Ranolazine—Hyperhidrosis—Doxorubicin—muscle cancer	0.002	0.00204	CcSEcCtD
Ranolazine—Anorexia—Doxorubicin—muscle cancer	0.00197	0.00201	CcSEcCtD
Ranolazine—Feeling abnormal—Methotrexate—muscle cancer	0.00197	0.00201	CcSEcCtD
Ranolazine—Gastrointestinal pain—Methotrexate—muscle cancer	0.00195	0.00199	CcSEcCtD
Ranolazine—Hypotension—Doxorubicin—muscle cancer	0.00193	0.00197	CcSEcCtD
Ranolazine—Urticaria—Methotrexate—muscle cancer	0.0019	0.00193	CcSEcCtD
Ranolazine—Abdominal pain—Methotrexate—muscle cancer	0.00189	0.00192	CcSEcCtD
Ranolazine—Insomnia—Doxorubicin—muscle cancer	0.00187	0.00191	CcSEcCtD
Ranolazine—Paraesthesia—Doxorubicin—muscle cancer	0.00186	0.00189	CcSEcCtD
Ranolazine—Dyspnoea—Doxorubicin—muscle cancer	0.00184	0.00188	CcSEcCtD
Ranolazine—Somnolence—Doxorubicin—muscle cancer	0.00184	0.00187	CcSEcCtD
Ranolazine—Dyspepsia—Doxorubicin—muscle cancer	0.00182	0.00186	CcSEcCtD
Ranolazine—Decreased appetite—Doxorubicin—muscle cancer	0.0018	0.00183	CcSEcCtD
Ranolazine—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.00179	0.00182	CcSEcCtD
Ranolazine—Fatigue—Doxorubicin—muscle cancer	0.00178	0.00182	CcSEcCtD
Ranolazine—Constipation—Doxorubicin—muscle cancer	0.00177	0.0018	CcSEcCtD
Ranolazine—Asthenia—Methotrexate—muscle cancer	0.00171	0.00175	CcSEcCtD
Ranolazine—Feeling abnormal—Doxorubicin—muscle cancer	0.00171	0.00174	CcSEcCtD
Ranolazine—Gastrointestinal pain—Doxorubicin—muscle cancer	0.00169	0.00172	CcSEcCtD
Ranolazine—Pruritus—Methotrexate—muscle cancer	0.00169	0.00172	CcSEcCtD
Ranolazine—Urticaria—Doxorubicin—muscle cancer	0.00164	0.00168	CcSEcCtD
Ranolazine—Abdominal pain—Doxorubicin—muscle cancer	0.00164	0.00167	CcSEcCtD
Ranolazine—Dizziness—Methotrexate—muscle cancer	0.00158	0.00161	CcSEcCtD
Ranolazine—Vomiting—Methotrexate—muscle cancer	0.00152	0.00155	CcSEcCtD
Ranolazine—Rash—Methotrexate—muscle cancer	0.00151	0.00154	CcSEcCtD
Ranolazine—Dermatitis—Methotrexate—muscle cancer	0.00151	0.00153	CcSEcCtD
Ranolazine—Headache—Methotrexate—muscle cancer	0.0015	0.00153	CcSEcCtD
Ranolazine—Asthenia—Doxorubicin—muscle cancer	0.00148	0.00151	CcSEcCtD
Ranolazine—Pruritus—Doxorubicin—muscle cancer	0.00146	0.00149	CcSEcCtD
Ranolazine—Nausea—Methotrexate—muscle cancer	0.00142	0.00145	CcSEcCtD
Ranolazine—Dizziness—Doxorubicin—muscle cancer	0.00137	0.00139	CcSEcCtD
Ranolazine—Vomiting—Doxorubicin—muscle cancer	0.00132	0.00134	CcSEcCtD
Ranolazine—Rash—Doxorubicin—muscle cancer	0.0013	0.00133	CcSEcCtD
Ranolazine—Dermatitis—Doxorubicin—muscle cancer	0.0013	0.00133	CcSEcCtD
Ranolazine—Headache—Doxorubicin—muscle cancer	0.0013	0.00132	CcSEcCtD
Ranolazine—Nausea—Doxorubicin—muscle cancer	0.00123	0.00125	CcSEcCtD
